Treatment with infliximab for pediatric Crohn's disease: Nationwide survey of Japan. Issue 1 (January 2017)

• Record Type: Journal Article
• Authors: Hosoi, Kenji; Ohtsuka, Yoshikazu; Fujii, Tohru; Kudo, Takahiro; Matsunaga, Nobuaki; Tomomasa, Takeshi; Tajiri, Hitoshi; Kunisaki, Reiko; Ishige, Takashi; Yamada, Hiroyuki; Arai, Katsuhiro; Yoden, Atsushi; Ushijima, Kosuke; Aomatsu, Tomoki; Nagata, Satoru; Uchida, Keiichi; Takeuchi, Kazuo; Shimizu, Toshiaki
• Is Part Of: Journal of gastroenterology and hepatology. Volume 32:Issue 1(2017)
• Page Start: 114
• Page End: 119
• Publication Date: 2017-01
• Subjects: Crohn's disease -- infliximab -- surgery -- ulcerative colitis; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Liver Diseases -- Periodicals; 616.33
• DOI: 10.1111/jgh.13498
• Languages: English
• ISSNs: 0815-9319

Abstract

Abstract: Background and Aim: Childhood‐onset inflammatory bowel disease (IBD) is characterized by extensive intestinal involvement and rapid early progression. Infliximab (IFX), cyclosporin (CYA), and tacrolimus (FK506) are increasingly used to treat pediatric IBD; however, their long‐term effects and adverse events have not been properly investigated in pediatric patients. The aim of this study was to characterize the effects of these biologics and immunomodulators on pediatric IBD patients in Japan. Additionally, we assessed IFX use in pediatric patients with Crohn's disease (CD). Methods: A national survey of IFX, adalimumab, CYA, and FK506 use in pediatric IBD patients (< 17 years of age) was sent to 683 facilities in Japan from December 2012 to March 2013. Secondary questionnaires were sent to pediatric and adult practitioners with the aim of assessing the effectiveness and safety of IFX for pediatric CD patients. Results: The response rate for the primary survey was 61.2% ( N = 418). Among 871 pediatric CD patients, 284 (31.5%), 24, 4, and 15 received IFX (31.5%), adalimumab, CYA, and FK506, respectively, from 2000 to 2012. According to the secondary survey, extensive colitis (L3, Paris classification) was diagnosed in 69.4% of pediatric CD patients who received IFX. Regarding the effectiveness of IFX in this population, 54.7% (99/181) of patients were in remission, and 42.0% (76/181) were on maintenance therapy. However, 32.0% (58/181) of patients experienced adverse events, and one patient died of septic shock. Conclusions: Infliximab is reasonably safe and effective in pediatric CD patients and should therefore be administered in refractory cases.